LIPO LIPELLA PHARMACEUTICALS INC.
Pharmaceutical Preparations · OTC · SEC CIK 1347242 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.4%
TTM net income YoY-25.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,387.9%
Net margin-1,367.4%
FCF margin—
EBITDA margin-1,387.2%
Returns
ROE-361.8%
ROA-236.4%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-24.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $536,357 | $449,617 | $184,156 | $259,347 |
| R&D expense | $3.61M | $3.04M | $2.55M | $1.46M |
| SG&A expense | $2.00M | $2.16M | $226,192 | $718,384 |
| Operating income | -$5.08M | -$4.75M | -$2.59M | -$1.92M |
| Interest expense | — | $10,848 | $9,612 | $6,834 |
| Pretax income | -$5.02M | -$4.62M | -$2.60M | -$1.87M |
| Net income | -$5.02M | -$4.62M | -$2.60M | -$1.87M |
| EBITDA | -$5.08M | -$4.74M | -$2.59M | -$1.92M |
| EPS (basic) | -4.79 | -6.16 | -0.64 | -0.55 |
| EPS (diluted) | -4.79 | -6.16 | -0.64 | -0.55 |
| Weighted avg. shares (diluted) | 1.05M | 750,383 | 4.06M | 3.41M |
| Balance sheet | ||||
| Cash & equivalents | $2.18M | $3.29M | $5.12M | $1.41M |
| Short-term investments | — | — | — | $300,546 |
| Receivables | $84,713 | $32,286 | $113,655 | — |
| Current assets | $2.62M | $3.43M | $5.80M | $1.81M |
| PP&E, net | $9,864 | $12,750 | — | — |
| Total assets | $2.67M | $3.58M | $5.95M | $2.01M |
| Current liabilities | $754,417 | $385,355 | $1.18M | $340,625 |
| Total liabilities | $754,417 | $432,726 | $1.27M | $589,337 |
| Shareholders' equity | $1.92M | $3.14M | $4.68M | $1.42M |
| Shares outstanding | 1.21M | 756,743 | 5.74M | 3.87M |
| Cash flow statement | ||||
| Operating cash flow | -$3.95M | -$3.15M | -$1.83M | -$989,271 |
| Capital expenditure | — | $14,434 | — | — |
| Free cash flow | — | -$3.16M | — | — |
| Investing cash flow | — | -$14,434 | $300,546 | -$300,546 |
| Financing cash flow | $2.84M | $1.34M | $5.24M | $2.10M |
| Depreciation & amortization | $2,886 | $1,685 | $0 | $0 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.